$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000162828020011994 Filed on August 06, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$66.34M	$53.98M	$36.66M
YoY Change	22.9%	178.48%	119.6%
Cost Of Revenue	$22.44M	$16.83M	$13.54M
YoY Change	33.33%	68.98%	46.38%
Gross Profit	$43.90M	$37.14M	$23.12M
YoY Change	18.2%	294.27%	210.75%
Gross Profit Margin	66.18%	68.81%	63.07%
Selling, General & Admin	$62.20M	$32.88M	$30.47M
YoY Change	89.19%	59.82%	70.87%
% of Gross Profit	141.69%	88.52%	131.78%
Research & Development	$36.32M	$19.53M	$16.32M
YoY Change	85.95%	69.05%	97.65%
% of Gross Profit	82.73%	52.59%	70.57%
Depreciation & Amortization	$3.200M	$2.200M	$2.354M
YoY Change	45.45%	69.23%	68.75%
% of Gross Profit	7.29%	5.92%	10.18%
Operating Expenses	$98.52M	$52.41M	$46.78M
YoY Change	87.98%	63.14%	79.35%
Operating Profit	-$54.62M	-$15.27M	-$23.66M
YoY Change	257.74%	-32.75%	26.91%
Interest Expense	$10.00K	$287.0K	$293.0K
YoY Change	-96.52%	-9.46%	-11.48%
% of Operating Profit
Other Income/Expense, Net	$2.285M	-$51.00K	$147.0K
YoY Change	-4580.39%	-112.91%	-96.46%
Pretax Income	-$49.71M	-$12.51M	-$21.33M
YoY Change	297.42%	-42.19%	54.04%
Income Tax	$34.00K	-$1.207M	$26.00K
% Of Pretax Income
Net Earnings	-$49.74M	-$11.30M	-$21.35M
YoY Change	340.17%	-47.78%	54.23%
Net Earnings / Revenue	-74.98%	-20.94%	-58.25%
Basic Earnings Per Share	-$0.57
Diluted Earnings Per Share	-$0.57	-$130.3K	-$303.1K
COMMON SHARES
Basic Shares Outstanding	96.01M shares	87.11M shares	85.93M shares
Diluted Shares Outstanding	96.01M shares

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$937.8M	$545.6M	$466.9M
YoY Change	71.88%	107.14%
Cash & Equivalents	$164.7M	$174.7M	$153.8M
Short-Term Investments	$773.2M	$371.0M	$313.1M
Other Short-Term Assets	$11.10M	$4.100M	$6.200M
YoY Change	170.73%	36.67%
Inventory	$20.35M	$14.18M	$10.26M
Prepaid Expenses
Receivables	$41.02M	$40.36M	$40.60M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.010B	$604.2M	$512.3M
YoY Change	67.2%	112.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.00M	$34.81M	$30.58M
YoY Change	63.73%	18.81%
Goodwill	$3.290M
YoY Change
Intangibles	$17.15M	$8.987M
YoY Change	90.81%
Long-Term Investments	$146.1M	$277.3M	$25.90M
YoY Change	-47.31%	633.6%
Other Assets	$5.124M	$3.159M	$2.862M
YoY Change	62.2%	-73.89%
Total Long-Term Assets	$267.2M	$335.7M	$66.92M
YoY Change	-20.41%	324.99%
TOTAL ASSETS
Total Short-Term Assets	$1.010B	$604.2M	$512.3M
Total Long-Term Assets	$267.2M	$335.7M	$66.92M
Total Assets	$1.278B	$940.0M	$579.2M
YoY Change	35.91%	159.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.98M	$15.70M	$7.163M
YoY Change	1.8%	82.56%
Accrued Expenses	$24.06M	$11.09M	$9.137M
YoY Change	116.87%	-31.11%
Deferred Revenue	$11.49M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$100.0K	$100.0K
YoY Change		0.0%
Total Short-Term Liabilities	$70.05M	$57.05M	$48.19M
YoY Change	22.79%	91.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$100.0K	$100.0K
YoY Change	-100.0%	-50.0%
Other Long-Term Liabilities	$1.382M	$1.303M	$150.0K
YoY Change	6.06%	-91.37%
Total Long-Term Liabilities	$1.382M	$1.303M	$150.0K
YoY Change	6.06%	-91.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$70.05M	$57.05M	$48.19M
Total Long-Term Liabilities	$1.382M	$1.303M	$150.0K
Total Liabilities	$112.5M	$77.72M	$64.54M
YoY Change	44.82%	-9.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$435.2M	-$314.8M	-$275.9M
YoY Change	38.24%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.115B	$815.5M	$468.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.278B	$940.0M	$579.2M
YoY Change	35.91%	159.09%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$49.74M	-$11.30M	-$21.35M
YoY Change	340.17%	-47.78%	54.23%
Depreciation, Depletion And Amortization	$3.200M	$2.200M	$2.354M
YoY Change	45.45%	69.23%	68.75%
Cash From Operating Activities	-$23.37M	-$13.84M	-$4.303M
YoY Change	68.86%	-18.78%	-34.4%
INVESTING ACTIVITIES
Capital Expenditures	-$9.510M	-$3.040M	$2.705M
YoY Change	212.83%	-58.58%	-32.73%
Acquisitions
YoY Change
Other Investing Activities	-$316.0M	-$317.5M	$18.03M
YoY Change	-0.45%	-1764.81%	44.36%
Cash From Investing Activities	-$325.6M	-$320.5M	$15.33M
YoY Change	1.57%	-2832.57%	80.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	361.3M	355.1M	$2.288M
YoY Change	1.76%	771.77%	80.58%
NET CHANGE
Cash From Operating Activities	-23.37M	-13.84M	-$4.303M
Cash From Investing Activities	-325.6M	-320.5M	$15.33M
Cash From Financing Activities	361.3M	355.1M	$2.288M
Net Change In Cash	12.40M	20.70M	$13.25M
YoY Change	-40.1%	-41.56%	316.77%
FREE CASH FLOW
Cash From Operating Activities	-$23.37M	-$13.84M	-$4.303M
Capital Expenditures	-$9.510M	-$3.040M	$2.705M
Free Cash Flow	-$13.86M	-$10.80M	-$7.008M
YoY Change	28.33%	11.34%	-33.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38683
	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 Penobscot Dr.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	855
	dei	Local Phone Number LocalPhoneNumber	698-8887
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001
	dei	Trading Symbol TradingSymbol	GH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99424269	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164671000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143228000	USD
CY2020Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	773160000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	379574000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41017000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47986000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	20354000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	15181000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11101000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11389000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	1010303000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	597358000	USD
CY2020Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	146118000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	268783000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56995000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43668000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38503000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29140000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17148000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8524000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	3290000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q2	gh	Capitalized License Fees CapitalizedLicenseFees	55000	USD
CY2019Q4	gh	Capitalized License Fees CapitalizedLicenseFees	6890000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5124000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4882000	USD
CY2020Q2	us-gaap	Assets Assets	1277536000	USD
CY2019Q4	us-gaap	Assets Assets	962535000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	15982000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16197000	USD
CY2020Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	18526000	USD
CY2019Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	18557000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24055000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25703000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11485000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12277000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	70048000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72734000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41117000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33256000	USD
CY2020Q2	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	0	USD
CY2019Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	6880000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1382000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1672000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	112547000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	114542000	USD
CY2020Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	50400000	USD
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	49600000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99312237	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99312237	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94261414	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94261414	shares
CY2020Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1544373000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1150090000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5392000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1111000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-435177000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-352809000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1114589000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	798393000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1277536000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	962535000	USD
CY2020Q2	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	50991000	USD
CY2019Q2	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	42064000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	111237000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	70901000	USD
CY2020Q2	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	15344000	USD
CY2019Q2	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	11911000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	22608000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	19729000	USD
CY2020Q2	us-gaap	Revenues Revenues	66335000	USD
CY2019Q2	us-gaap	Revenues Revenues	53975000	USD
	us-gaap	Revenues Revenues	133845000	USD
	us-gaap	Revenues Revenues	90630000	USD
CY2020Q2	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	17809000	USD
CY2019Q2	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	14650000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	36000000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	25673000	USD
CY2020Q2	gh	Costof Development Services CostofDevelopmentServices	4626000	USD
CY2019Q2	gh	Costof Development Services CostofDevelopmentServices	2183000	USD
	gh	Costof Development Services CostofDevelopmentServices	6941000	USD
	gh	Costof Development Services CostofDevelopmentServices	4695000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36319000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13439000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56971000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26100000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19532000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73335000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35848000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25015000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19439000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	50130000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37246000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37186000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	120955000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	69243000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	223377000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	129562000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-54620000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15268000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	287000	USD
	us-gaap	Interest Expense InterestExpense	22000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89532000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38932000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2640000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3099000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5958000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5584000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	10000	USD
	us-gaap	Interest Expense InterestExpense	580000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2285000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2076000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	96000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-49705000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12507000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-81520000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33832000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1207000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1181000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11300000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
	us-gaap	Profit Loss ProfitLoss	-32651000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4900000	USD
CY2019Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	800000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	5000000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54639000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-82368000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37651000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	96011000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89036000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95196000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87494000	shares
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11300000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
	us-gaap	Profit Loss ProfitLoss	-32651000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2338000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	852000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4233000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1337000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	25000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	159000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	48000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	90000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2313000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1011000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4281000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1427000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-52052000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10289000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-77287000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-31224000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	4900000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	300000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	800000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	5000000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56952000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10589000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78087000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36224000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	785113000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1130000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2044000	USD
CY2020Q2	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3956000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25815000	USD
CY2020Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-4900000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2313000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1114589000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	468134000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	723000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349709000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4992000	USD
CY2019Q2	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3215000	USD
CY2019Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-300000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1011000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11300000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	815474000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	798393000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1130000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3548000	USD
	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	26000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3956000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32153000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-800000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4281000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1114589000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	483152000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	723000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349709000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5530000	USD
	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	69000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1933000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6398000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-5000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1427000	USD
	us-gaap	Profit Loss ProfitLoss	-32651000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	815474000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
	us-gaap	Profit Loss ProfitLoss	-32651000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7109000	USD
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	1435000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5011000	USD
	gh	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	3386000	USD
	gh	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	1633000	USD
	gh	Charge Of In Process Research And Development ChargeOfInProcessResearchAndDevelopment	8500000	USD
	gh	Charge Of In Process Research And Development ChargeOfInProcessResearchAndDevelopment	0	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	0	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	51000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-190000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32153000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6398000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1065000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1276000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1235000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-19000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2939000	USD
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3881000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6894000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-234000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5173000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5040000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-438000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1122000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	242000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1129000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2476000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3412000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-31000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	701000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1820000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-792000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	358000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36647000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18139000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	465302000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	418841000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	197548000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	129160000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9765000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19105000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5752000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17886000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-304745000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-305198000	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	0	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	151000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	79000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	62000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3548000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5530000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3956000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1933000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	355730000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	350432000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	369000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	326000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	362786000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	357356000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21443000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34109000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143228000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140544000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164671000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174653000	USD
	gh	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	761000	USD
	gh	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	486000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1135000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11373000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1565000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5396000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3874000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations, goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. The extent to which the COVID-19 pandemic will ultimately impact the </span></div>Company’s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company’s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Risk</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.</span></div>A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company’s total revenue or accounts receivable balance.
CY2020Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	6500000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3600000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	12400000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	6400000	USD
	gh	Contract With Customer Liability Cumulative Catch Up Adjustment To Prior Year Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress	-3600000	USD
CY2020Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	9500000	USD
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	6200000	USD
CY2020Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11500000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12300000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7600000	USD
	gh	Variable Interest Entity Threshold Percentageof Fair Valuethatis No Less Than Internal Rateof Return VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn	0.20
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.40
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.40
	us-gaap	Depreciation Depreciation	6200000	USD
	us-gaap	Depreciation Depreciation	4300000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	3200000	USD
CY2019Q2	us-gaap	Depreciation Depreciation	2200000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	84941000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	65591000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27946000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21923000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56995000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43668000	USD
CY2020Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	325000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1564000	USD
CY2020Q2	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	2598000	USD
CY2019Q4	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	2029000	USD
CY2020Q2	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	1476000	USD
CY2019Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	1046000	USD
CY2020Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3268000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3050000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3275000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3464000	USD
CY2020Q2	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	1734000	USD
CY2019Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	2424000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8240000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7140000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3139000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4986000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24055000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25703000	USD
CY2020Q2	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	933892000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5623000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q2	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	939515000	USD
CY2019Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	657696000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1434000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	USD
CY2019Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	659091000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16986000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1438000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15548000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q2	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1438000	USD
CY2020Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	20438000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	7600000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	676000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6924000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2019Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	12490000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	676000	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11814000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4312500	shares
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	84.00
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	994000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1947000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1947000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1947000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1953000	USD
CY2020Q2	gh	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	6760000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15548000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1900000	USD
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3400000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1600000	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0819
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0777
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4723000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11619000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9840000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10535000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10780000	USD
CY2020Q2	gh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	20251000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	67748000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18391000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	49357000	USD
CY2017Q4	us-gaap	Gain Contingency Patents Allegedly Infringed Upon Number GainContingencyPatentsAllegedlyInfringedUponNumber	4	patent
CY2018Q3	us-gaap	Gain Contingency Patents Allegedly Infringed Upon Number GainContingencyPatentsAllegedlyInfringedUponNumber	4	patent
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8871905	shares
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8407162	shares
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5175000	shares
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	71.00
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349700000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2726225	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4494889	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.90
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	306392000	USD
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Annual Increase In Shares Available SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	78476	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	78476	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	76.01
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	654557	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.42
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	12406	shares
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-49739000	USD
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	150268000	USD
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Annual Increase In Shares Available SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	49806	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.79
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2864528	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3869002	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.18
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	266316000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2014893	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.90
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	44.61
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	51.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	43.35
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6398000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25815000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3215000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32153000	USD
	us-gaap	Profit Loss ProfitLoss	-81568000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
	us-gaap	Profit Loss ProfitLoss	-32651000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4900000	USD
CY2019Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	800000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	5000000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54639000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-82368000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37651000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	96011000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89036000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95196000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87494000	shares
	us-gaap	Revenues Revenues	90630000	USD
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5997000	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6550000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5451000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7116000	shares
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1200000	USD
CY2020Q2	us-gaap	Revenues Revenues	66335000	USD
CY2019Q2	us-gaap	Revenues Revenues	53975000	USD
	us-gaap	Revenues Revenues	133845000	USD

Files In Submission

Name	View Source	Status
0001628280-20-011994-index-headers.html	Edgar Link	pending
0001628280-20-011994-index.html	Edgar Link	pending
0001628280-20-011994.txt	Edgar Link	pending
0001628280-20-011994-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-0630x2020x10qxex311.htm	Edgar Link	pending
gh-0630x2020x10qxex312.htm	Edgar Link	pending
gh-0630x2020x10qxex321.htm	Edgar Link	pending
gh-0630x2020x10qxex322.htm	Edgar Link	pending
gh-20200630.htm	Edgar Link	pending
gh-20200630.xsd	Edgar Link	pending
gh-20200630_cal.xml	Edgar Link	unprocessable
gh-20200630_def.xml	Edgar Link	unprocessable
gh-20200630_htm.xml	Edgar Link	completed
gh-20200630_lab.xml	Edgar Link	unprocessable
gh-20200630_pre.xml	Edgar Link	unprocessable
gh-directorcompensatio.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2020 Q2 Form 10-Q Financial Statement

#000162828020011994 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2020 Q2 Form 10-Q Financial Statement

#000162828020011994 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh